Navigation Links
Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:9/6/2011

NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Coronado Biosciences, Inc. (the "Company"), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Dr. Bobby Sandage, the Company's President, Chief Executive Officer and Director, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 10:50 AM ET.  The conference will be held at The Waldorf Astoria Hotel in New York City on September 11-13, 2011.

A webcast of this presentation will be available at www.coronadobiosciences.com on the events page.  

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.

The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012.  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact Information:

Investor Relations
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159


'/>"/>
SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences Files to Become a Public Reporting Company
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
4. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
5. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
6. Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
8. Magellan Biosciences Sells TREK Microbiology Business to Thermo Fisher Scientific
9. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
10. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
11. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , , Marks E-QURE , ... agreement, following similar agreements in Israel and ... 5 billion global market ... leader in medical devices for the treatment of advanced wound care, announced today ... in Colombia for the Company,s patented Bio-electrical Signal Therapy ...
(Date:1/19/2017)... Jan. 18, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... introducing the Aerolib Learning Management System: an On-demand E-learning system for Clinical ... and Hospital Administration that is based on Aerolib`s successful education methodology of ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... SF expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, ... growing demand of physicians and patients throughout the United States for high-quality human ...
(Date:1/19/2017)... ... 2017 , ... This month, the CEO and Clinical Director of Sober Living ... center in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO ... Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed ...
(Date:1/19/2017)... ... 19, 2017 , ... WhoHaha , a digital media company dedicated to ... (AHA) to produce a three-part video series that uses humor to highlight ways to ... launch of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans ...
(Date:1/19/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 with ... easier for their readers to get the information they desire. The procedures are now ... techniques used on those particular areas. , “We are excited to streamline our listings ...
Breaking Medicine News(10 mins):